Evolent Health Inc. ((EVH)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evolent Health’s latest earnings call struck a cautiously optimistic tone, blending strong growth prospects with clear near‑term pressure. Management highlighted robust revenue momentum, major new contracts and improving medical margins, yet also flagged exchange‑related revenue losses, conservative reserving and modest cash generation that will weigh on 2026 profitability.
Q4 Beat Underscores Solid Finish to 2025
Evolent reported Q4 revenue of $469 million and adjusted EBITDA of $37.8 million, topping the midpoint of guidance. The quarter’s outperformance sets a firmer base heading into 2026, even as management resets expectations around margin trajectory and cash conversion.
Baseline 2025 Earnings Power After ACO Sale
Excluding the divested ACO business, baseline 2025 revenue was $1.77 billion with adjusted EBITDA around $141 million. That context matters for investors, as it clarifies the underlying earnings power of the continuing operations on which 2026 guidance is built.
Bold 2026 Revenue Ambition Around 30% Growth
For 2026, Evolent is targeting revenue of $2.4 billion to $2.6 billion, implying roughly 30% growth at the $2.5 billion midpoint. This step‑up reflects both organic expansion and the ramp of new Performance Suite contracts that are reshaping the company’s scale and mix.
Performance Suite Cohort Swells to $900 Million
New Performance Suite launches in 2026 are now expected to produce about $900 million of revenue, or 37% of the year’s total, up sharply from a prior $550 million estimate. The upgrade is driven by membership shifts and expanded scope, underscoring strong demand for the company’s value‑based offerings.
Oncology Becomes the Core Revenue Engine
Oncology is rapidly becoming Evolent’s centerpiece, projected to represent roughly 65% of company revenue in 2026 versus 36% in 2025. This concentration highlights both the momentum in cancer care management and the company’s increasing exposure to one specialty vertical.
High Retention and Shift to Enhanced Contract Model
Evolent retained specialty technology and services customers representing more than 98% of 2025 revenue, while about 90% of Performance Suite revenue has migrated to the enhanced model. A marquee win is Highmark, expected to contribute over $550 million in 2026 and more than $800 million in 2027 as the contract ramps.
MER Improvement Signals Better Medical Management
The 2025 medical expense ratio, excluding ECP, improved to 89%, nearly 700 basis points better than 2024. Management credited tighter pathway management and greater physician engagement, suggesting that care management programs are delivering tangible cost and quality gains.
Cost Discipline and AI Deliver Structural Savings
Evolent exceeded its previously announced $20 million in annualized Q4 2025 savings and is targeting roughly $50 million of efficiency gains in 2026. Non‑claims expenses are expected to fall to about $675 million, roughly $90 million below 2025, combining divestiture impact with automation and AI‑driven cost cuts.
Balance Sheet Stable With No Near‑Term Maturities
The company ended the year with net debt of $782 million, better than its $805 million to $840 million expectation range. Importantly, Evolent faces no debt maturities until late 2029, giving management time to grow earnings before confronting major refinancing needs.
Operational and Clinical Wins Strengthen the Value Proposition
AI‑driven auto‑authorization gains, including an 11‑point improvement for chest CT and 16 points for cervical spine MRI, illustrate ongoing productivity improvements. A Blue Cross partner reported around a 40% reduction in hospitalizations and ER visits from Evolent’s cancer navigation solution, reinforcing the clinical and economic case.
Exchange Membership Contraction Hits Revenue
The so‑called One Big Beautiful Bill and related market shifts removed roughly $40 million of contribution tied to exchange membership. Some customers saw exchange enrollment fall by as much as about 60%, materially hurting revenue mix despite growth in other lines like Medicare Advantage.
Conservative MER Guidance and Elevated New‑Cohort Reserves
For 2026, Evolent is guiding to a full‑book MER of around 93% at the midpoint, up from 89% in 2025 excluding ECP. The new Performance Suite cohort is reserved at a roughly 103% MER for 2026, reflecting cautious assumptions as contracts launch and data credibility builds.
New Launches Depress Near‑Term EBITDA
Those conservative reserves and early implementation costs for new Performance Suite deals are expected to create about a $25 million headwind to 2026 adjusted EBITDA at the midpoint. Overall, management guided 2026 adjusted EBITDA to a range of $110 million to $140 million, with a midpoint of $125 million.
EBITDA Skewed to Second Half Amid Disappointing H1
Around 70% of 2026 adjusted EBITDA is expected to land in the back half of the year, as new contracts mature and reserving normalizes. Management acknowledged that first‑half EBITDA will look weak on the surface, but argued that exit‑run‑rate earnings will be substantially stronger.
Administrative Services Churn Highlights Legacy Risk
The company saw notable churn in its administrative services business after one customer was acquired and chose to insource. Management framed this as a legacy portfolio with ongoing attrition risk, reinforcing the strategic pivot toward the more scalable Performance Suite model.
Free Cash Flow Tight as Interest Costs Weigh
Evolent expects only $10 million to $20 million in cash from operations during 2026 after paying about $60 million in cash interest, following $39 million of operating cash flow in 2025. Year‑end cash stood at $152 million, including a $15 million client overpayment that will reverse in 2026, constraining near‑term financial flexibility.
Noncash Goodwill Impairment Clouds GAAP Optics
The company recorded a significant noncash goodwill impairment driven by lower market valuations, pressuring reported GAAP earnings and book value. Management stressed that the charge has no impact on EBITDA or cash flow, but it does add optical noise for headline valuation metrics.
Leverage Limits Liability‑Management Options
Leverage is expected to be higher early in 2026 as new contracts ramp and EBITDA lags, limiting capacity for actions like share repurchases or discounted debt buybacks. While the convertible debt trades at a discount, management signaled that balance‑sheet constraints preclude aggressive liability management near term.
Revenue Mix Pressure Lowers Blended PMPM
Exchange losses and shifts toward lower per‑member‑per‑month cohorts have diluted some of Evolent’s organic growth, even as membership rose in other lines. The resulting pressure on blended PMPM and revenue mix is an important watchpoint for investors tracking the quality of top‑line expansion.
Restructuring and Workforce Reduction Bring Execution Risk
To unlock the targeted efficiency gains, Evolent executed a sizable reduction in force and related restructuring moves. While these actions support the lower cost base, they present near‑term execution risk as the organization absorbs change and maintains service levels.
Guidance Points to Strong Exit Run‑Rate Despite 2026 Dip
Management’s 2026 outlook calls for $2.4 billion to $2.6 billion in revenue and $110 million to $140 million in adjusted EBITDA, with Q4 run‑rate EBITDA expected above $150 million. With Performance Suite revenue projected at about $2.2 billion annualized exiting 2026 and long‑term margins in the 7% to 10% range, management sees meaningful earnings upside as contracts normalize and cost cuts take hold.
Evolent’s earnings call painted a company in transition, trading near‑term margin and cash pressure for scale and contract quality in oncology and value‑based care. For investors, the story hinges on whether the promised back‑half 2026 inflection and longer‑term Performance Suite margins materialize, turning today’s growing pains into durable earnings power.